Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's Top Device Maker Mindray Enters Critical Care Market; Sees Boosts From Color Ultrasound Devices

This article was originally published in PharmAsia News

Executive Summary

Despite a negative impact from political unrest in the Middle East, China's leading medical device maker Mindray Medical International is steaming ahead with solid first quarter growth in both international and Chinese domestic markets. That growth was driven largely by a continued stronghold in its low- to mid-end device market, as well as an emerging footprint in the lucrative high-end segment with its color ultrasound devices

You may also be interested in...



Lower-Tier Hospitals Will See More Medical Device Growth In 2013: Citi Hospital Survey

Spending on new medical equipment by top-tier hospitals in China is expected to ease in 2013, but still show double-digit growth with multinationals like General Electric competing with domestic firms led by Mindray Medical.

China’s Mindray Expands Market With Increased R&D And Acquisitions

Mindray expects to hold its own amidst foreign competition, including in the high-end device market thanks to acquisitions and R&D investments that have boosted its technological capability.

Kanghui Bullish On Joint Implants Despite Looming Price Cuts; Mindray Undercutting U.S. Competition: China Earnings Roundup (Part 4)

Regulatory headwinds and price cuts led to a massive slowdown in China’s pharmaceutical industry in Q3, but China’s device makers are still enjoying fast growth.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC077921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel